Song Da 5 JSC (HNX:SD5)

CTI BioPharma Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,867,690	2,337,133	2,262,146	1,800,779	2,147,950	1,727,769
Revenue Growth (YoY)	16.13%	3.31%	25.62%	-16.16%	24.32%	48.77%
Cost of Revenue	2,770,814	2,247,319	2,192,352	1,718,405	2,071,421	1,649,146
Gross Profit	96,876	89,814	69,794	82,373	76,529	78,623
Selling, General & Admin	106,193	71,494	36,029	23,319	33,245	34,154
Operating Expenses	106,193	71,494	36,029	23,319	33,245	34,154
Operating Income	-9,316	18,320	33,765	59,055	43,284	44,469
Interest Expense	-63,580	-4,226	-22,831	-31,187	-25,912	-22,632
Interest & Investment Income	1,761	1,761	231.34	44,442	39,884	34,736
Currency Exchange Gain (Loss)	14,338	14,338	16,142	-	-	-
Other Non Operating Income (Expenses)	92,930	1,357	425.31	-46,309	-25,935	-17,717
EBT Excluding Unusual Items	36,132	31,550	27,733	26,000	31,321	38,856
Gain (Loss) on Sale of Assets	4,144	4,144	2,486	-	-	-
Other Unusual Items	-	-	600	-	-	-
Pretax Income	40,276	35,693	30,819	26,000	31,321	38,856
Income Tax Expense	13,547	12,047	9,768	8,561	9,756	9,825
Earnings From Continuing Operations	26,729	23,646	21,052	17,439	21,565	29,031
Net Income	26,729	23,646	21,052	17,439	21,565	29,031
Preferred Dividends & Other Adjustments	-	-	2,852	-	-	-
Net Income to Common	26,729	23,646	18,200	17,439	21,565	29,031
Net Income Growth	16.94%	12.32%	20.72%	-19.13%	-25.72%	55.47%
Shares Outstanding (Basic)	26	26	26	26	26	26
Shares Outstanding (Diluted)	26	26	26	26	26	26
Shares Change (YoY)	-0.08%	-	0.04%	-0.09%	0.09%	-0.07%
EPS (Basic)	1028.47	909.46	700.00	671.00	829.00	1117.00
EPS (Diluted)	1028.00	909.00	700.00	671.00	829.00	1117.00
EPS Growth	33.66%	29.86%	4.32%	-19.06%	-25.78%	55.57%
Free Cash Flow	105,171	171,951	198,800	210,530	-73,209	-4,135
Free Cash Flow Per Share	4046.75	6613.54	7646.21	8100.70	-2814.28	-159.09
Dividend Per Share	700.000	700.000	-	-	-	-
Gross Margin	3.38%	3.84%	3.08%	4.57%	3.56%	4.55%
Operating Margin	-0.33%	0.78%	1.49%	3.28%	2.02%	2.57%
Profit Margin	0.93%	1.01%	0.80%	0.97%	1.00%	1.68%
Free Cash Flow Margin	3.67%	7.36%	8.79%	11.69%	-3.41%	-0.24%
EBITDA	21,721	48,704	63,354	88,687	75,550	89,577
EBITDA Margin	0.76%	2.08%	2.80%	4.92%	3.52%	5.18%
D&A For EBITDA	31,037	30,384	29,589	29,632	32,265	45,108
EBIT	-9,316	18,320	33,765	59,055	43,284	44,469
EBIT Margin	-0.33%	0.78%	1.49%	3.28%	2.02%	2.57%
Effective Tax Rate	33.64%	33.75%	31.69%	32.93%	31.15%	25.29%
Revenue as Reported	2,867,690	2,337,133	2,262,146	1,800,779	2,147,950	1,727,769

Source: S&P Global Market Intelligence. Standard template. Financial Sources.